Regentis Biomaterials Strengthens Global IP Portfolio for GelrinC Manufacturing

Regentis Biomaterials (NYSE American: RGNT) is reinforcing the manufacturing and intellectual property foundation behind its GelrinC cartilage-repair technology as it moves toward broader commercialization. The company recently received a Japanese Notice of Allowance for patent protection covering the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC. This milestone follows a recent U.S. issuance that expanded its global IP portfolio to nearly 30 patents.

The proprietary manufacturing process increases yield fivefold, simplifies production, and is built to support commercial-scale manufacturing—important advantages for an off-the-shelf cartilage-repair product designed to avoid the complexity and cost of cell-based procedures. The process eliminates organic solvents, potentially reducing environmental impact and improving safety, while the ready-to-use formulation enhances convenience for surgeons.

This IP milestone comes as the company begins European commercialization efforts following CE Mark approval and advances its pivotal U.S. trial beyond 50% enrollment, with premarket approval preparation targeted for the end of 2027. The strengthening of its patent portfolio in key markets like Japan and the U.S. is crucial for protecting its innovative technology and ensuring market exclusivity as it scales up.

Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. The lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This approach aims to address a significant unmet medical need: approximately 470,000 cases of cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

The receipt of the Japanese Notice of Allowance is a strategic move to protect its manufacturing process in a major market, potentially paving the way for future market entry in Asia. The expanded IP portfolio, now nearing 30 patents globally, strengthens the company’s competitive position and may attract potential partners or investors. As Regentis advances its clinical and regulatory milestones, the robust IP protection ensures that its innovations remain safeguarded, which is vital for long-term growth and shareholder value.

For more information on Regentis Biomaterials, visit the company’s newsroom at https://ibn.fm/RGNT.